CRL vs REPL · rev $4.05B vs $825.7M cap
Charles River Laboratories (CRL) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
REPL does not have a complete income-statement cache yet.
CRL currently screens at market cap $7.78B. REPL currently screens at market cap $825.7M.
Not investment advice. Open the CRL and REPL stock pages for the full models.
Not investment advice.